What changed in Globus Medical, Inc.'s latest annual report
In the year ended 31 Dec 2025, Globus Medical, Inc.'s revenue rose 16.7% to USD 2.94bn, from USD 2.52bn; net income rose 422.3% to USD 537.87m, from USD 102.98m; cash and cash equivalents fell 32.9% to USD 526.16m, from USD 784.44m.
Year ended 31 Dec 2025. Source: 10-K filed 24 Feb 2026, read it on SEC EDGAR.
USD 2.52bn to USD 2.94bn
The figures, year on year
| Item | Year before | Latest year | Change |
|---|---|---|---|
| Revenue | 2.52bn | 2.94bn | Up 16.7% |
| Net income | 102.98m | 537.87m | Up 422.3% |
| Total assets | 5.25bn | 5.30bn | Up 1% |
| Total liabilities | 1.07bn | 729.51m | Down 32.1% |
| Cash and cash equivalents | 784.44m | 526.16m | Down 32.9% |
| Shareholders' equity | 4.18bn | 4.57bn | Up 9.5% |
Questions people ask
Did Globus Medical, Inc.'s revenue grow last year?
Revenue grew 16.7%, from USD 2.52bn to USD 2.94bn in the year ended 31 Dec 2025.
Is Globus Medical, Inc. profitable?
Yes. Net income was USD 537.87m in the year ended 31 Dec 2025. The year before: USD 102.98m.
How much cash and debt does Globus Medical, Inc. have?
At its latest year end (31 Dec 2025), Globus Medical, Inc. reported cash and cash equivalents of USD 526.16m.
Where do these numbers come from?
From Globus Medical, Inc.'s own annual filings with the SEC. Each change is calculated from the reported figures; nothing is estimated.
Meeting a client who works with Globus Medical, Inc.?
LYNORIQ remembers every client meeting the way this page tracks a filing: what changed since last time, what you promised, and what they owe you.
Start free See the demoOther Surgical & Medical Instruments & Apparatus companies
- Stryker CorpLong-term debt up 21.9%
- 3M CompanyShareholders' equity up 22.4%
- Boston Scientific CorporationCash and cash equivalents up 374.6%
- Becton, Dickinson And CompanyCash and cash equivalents down 62.7%
- Medline Inc.Cash and cash equivalents up 874.4%
- ResMed Inc.Long-term debt down 39.3%
- Dexcom, Inc.Cash and cash equivalents up 51.4%
- West Pharmaceutical Services, Inc.Cash and cash equivalents up 63.3%